Traders should anticipate upward revisions to revenue and gross profit expectations when Legend Biotech releases its full Q1 2026 financial results. The $597M sales figure implies strong demand for CARVYKTI®, supporting potential upside in stock valuation if sustained. Monitor upcoming earnings for confirmation and royalty rate clarity.
Price Chart
Executive Summary
Legend Biotech reported preliminary net trade sales of $597 million for CARVYKTI® in Q1 2026, based on data provided by partner Janssen. This reflects strong commercial performance of the CAR-T therapy, though the figure is unaudited and subject to final confirmation in Legend Biotech's upcoming financial statements.
Key Facts
- CARVYKTI® generated approximately $597 million in net trade sales during the quarter ended March 31, 2026
- Sales data provided by Janssen under the collaboration agreement; not independently verified or audited by Legend Biotech
- Figure represents preliminary information as of April 14, 2026, pending finalization of financial statements
- No revenue or gross profit recognition confirmed yet; subject to management completion and audit
Financial Impact
$597 million in net trade sales for CARVYKTI® in Q1 2026
Risk Factors
- Sales figure is preliminary and unaudited; final financials may differ
- Legend Biotech has not independently verified the data provided by Janssen
- Forward-looking statements are subject to risks including regulatory delays, IP challenges, and competition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002425 |
| Document: 0001171843-26-002425-index-headers.html | 0001171843-26-002425 |
| Document: 0001171843-26-002425-index.html | 0001171843-26-002425 |
| Document: 0001171843-26-002425.txt | 0001171843-26-002425 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers